| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8819837 | Respiratory Medicine | 2018 | 9 Pages |
Abstract
There remains uncertainty about the ideal second-line agent for MPM. Based on this meta-analysis, palliative chemotherapy or other experimental agents can be considered for patients with MPM who desire further treatment after their disease has progressed, during or after first-line therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Fausto Petrelli, Raffaele Ardito, Barbara Conti, Andrea Coinu, Mary Cabiddu, Mara Ghilardi, Karen Borgonovo, Sandro Barni, Antonio Ghidini,